FDA approves IND for clinical trial evaluating CBD-based drug

By Jenni Spinner

- Last updated on GMT

(Feodora Chiosea/iStock via Getty Images Plus)
(Feodora Chiosea/iStock via Getty Images Plus)

Related tags CBD Opioid Opioid epidemic Fda IND phase I

The agency has given the go-ahead on an IND application for a study evaluating Ananda Scientific’s Nantheia ATL5, a candidate for treating opioid use disorder.

Biotech pharmaceutical firm Ananda Scientific has announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a clinical study evaluating Nantheia ATL5. The candidate uses cannabidiol (CBD) with the company’s proprietary delivery technology as an adjunctive treatment for opioid use disorder.

According to Ananda Scientific representatives, the study is planned to take place at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at the University of California-Los Angeles (UCLA).

Sohail Zaidi, CEO, of Ananda Scientific

Sohail Zaidi, CEO of Ananda Scientific, said the IND approval is the latest in a line of promising developments for the company’s offerings.

This is the fourth IND approval for our investigational drug Nantheia product line, and it further re-enforces our vision of developing CBD as a therapeutic for a number of key indications​,” Zaidi said. “This clinical study at UCLA is an important component of our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet need; we are excited to be working with the UCLA team and look forward to this trial advancing​.”

This particular trial is being led by principal investigators (PIs)

OSP_AnandaCBD_EL
Edythe London, Jane and Terry Semel Institute at David Geffen School of Medicine, UCLA

; and Richard De La Garza, Professor of Psychiatry and Biobehavioral Sciences at the Jane and Terry Semel Institute at David Geffen School of Medicine UCLA. Additionally, funding for the trial reportedly is coming from the National Institute on Drug Abuse (NIDA).

PI London said, “The approval of the IND for this important clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic.”

OSP_AnandaCBD_RD
Richard De La Garza, Jane and Terry Semel Institute at David Geffen School of Medicine, UCLA

With the IND approved we are now moving quickly to get the trial underway​,” added De La Garza.

Related news

Related products

show more

The Complete Guide to eRegulatory and eSource

The Complete Guide to eRegulatory and eSource

Florence Healthcare | 01-Apr-2023 | Insight Guide

Shifting to eRegulatory and eSource workflows is a requirement for clinical trial sites to continue to scale and grow their studies. This guide is designed...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

Related suppliers

Follow us

Products

View more

Webinars